Explore

Trendline Trendline
Biogen Stock Rises Following Analyst Upgrade and Acquisition of Drug Rights

Biogen Stock Rises Following Analyst Upgrade and Acquisition of Drug Rights

Biogen Stock Rises Following Analyst Upgrade and Acquisition of Drug Rights
Trendline Trendline
Analysts Issue Mixed Ratings on Major Tech and Energy Companies

Analysts Issue Mixed Ratings on Major Tech and Energy Companies

Analysts Issue Mixed Ratings on Major Tech and Energy Companies
Reuters Reuters
TopBuild shares jump after $17 billion QXO deal

TopBuild shares jump after $17 billion QXO deal

April 20 (Reuters) - Shares of U.S. building products distributor and installer TopBuild jumped nearly 20% in premarket trading on Monday, a day after the company agreed to be acquired by construction supplies distributor QXO in a $17 billion deal amid industry-wide consolidation. 
Trendline Trendline
Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment
Reuters Reuters
Jack Daniel's maker Brown-Forman favors Pernod Ricard bid over Sazerac, source says

Jack Daniel's maker Brown-Forman favors Pernod Ricard bid over Sazerac, source says

By Echo Wang and Abigail Summerville April 20 (Reuters) - The family that controls Jack Daniel's maker Brown-Forman favors a potential sale to French distiller Pernod Ricard over a rival proposal from American spirits group Sazerac, a person familiar with the matter told Reuters on Monday.
Trendline Trendline
Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action

Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action

Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action
Reuters Reuters
Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

April 19 (Reuters) - U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. 
Trendline Trendline
Kaskela Law Challenges Clearwater Analytics Buyout Over Alleged Unfair Pricing

Kaskela Law Challenges Clearwater Analytics Buyout Over Alleged Unfair Pricing

Kaskela Law Challenges Clearwater Analytics Buyout Over Alleged Unfair Pricing
Trendline Trendline
Rosen Law Firm Urges Navan, Inc. Investors to Act Before April 24 Deadline in Securities Class Action

Rosen Law Firm Urges Navan, Inc. Investors to Act Before April 24 Deadline in Securities Class Action

Rosen Law Firm Urges Navan, Inc. Investors to Act Before April 24 Deadline in Securities Class Action
Trendline Trendline
Kaskela Law Challenges Clearwater Analytics Buyout Proposal, Citing Unfair Shareholder Compensation

Kaskela Law Challenges Clearwater Analytics Buyout Proposal, Citing Unfair Shareholder Compensation

Kaskela Law Challenges Clearwater Analytics Buyout Proposal, Citing Unfair Shareholder Compensation
Trendline Trendline
Kaskela Law Challenges Clearwater Analytics Buyout Proposal Over Fairness Concerns

Kaskela Law Challenges Clearwater Analytics Buyout Proposal Over Fairness Concerns

Kaskela Law Challenges Clearwater Analytics Buyout Proposal Over Fairness Concerns
Trendline Trendline
Rosen Law Firm Investigates Enphase Energy for Alleged Misleading Statements Affecting Investors

Rosen Law Firm Investigates Enphase Energy for Alleged Misleading Statements Affecting Investors

Rosen Law Firm Investigates Enphase Energy for Alleged Misleading Statements Affecting Investors